If you regularly drink high-caffeine energy drinks, pre-workout supplements, or energy shots — and you are under 35 — a new review presented at the American Heart Association‘s scientific meeting carries information worth understanding before your next can.
The energy drinks cardiac arrest study reviewed 28,345 adverse event reports submitted to the FDA between 2017 and 2025 through the agency’s FAERS voluntary reporting database. Researchers found that caffeine and stimulant supplements were associated with an 11-fold higher rate of reported cardiac arrest compared to non-stimulant products. The data also showed a 4.5-fold increase in reported heart attacks and a 4-fold increase in ventricular arrhythmias and palpitations. The findings showed a particular concentration of cardiac arrest reports among adults aged 18 to 34. The research was presented at the AHA Scientific Sessions on November 2, 2026. Dr. Gregory M. Marcus of UCSF Cardiology, who was not involved in the study, provided expert commentary on the findings.
Young adults who routinely consume high-dose energy drinks should evaluate their daily stimulant intake, particularly when combining energy beverages with pre-workout formulas. While the AHA data reflects reporting associations rather than direct laboratory causation, the eleven-fold correlation with cardiac arrest points to serious vulnerability for individuals with undiagnosed rhythm disorders. Anyone experiencing sudden palpitations, dizziness, or chest tightness after consuming caffeinated stimulants should discontinue use and seek immediate medical evaluation.
What the Study Found — and What It Can’t Confirm
The research does not prove that energy drinks directly cause cardiac arrest. The data comes from voluntary adverse event reports — people who consumed a product and then reported a health incident — not a controlled clinical trial. Researchers explicitly acknowledge they cannot account for underlying undiagnosed heart conditions, simultaneous alcohol use, dehydration, or other compounding factors in the reporting population. The AHA abstract is also preliminary and has not yet completed full peer review. Dr. Marcus confirmed that the study does not prove that caffeine products cause these events, because other factors may have influenced the results.
What the data can confirm is that the reporting association is large enough to be medically relevant. An 11-fold correlation is a substantial statistical signal even in a database with known reporting limitations. High caffeine doses can trigger dangerous arrhythmias, particularly in people who carry an undiagnosed rhythm disorder with no prior symptoms.
Caffeine content varies widely between energy drinks and stimulant products. Consumers who regularly use multiple high-caffeine products in the same day — stacking an energy drink with a pre-workout supplement, for example — should be aware that total daily intake from combined products can reach levels that medical experts consider elevated risk territory for individuals with undetected heart conditions.
These findings are expected to renew attention to FDA labeling policy on high-caffeine beverages. Prior coverage on caffeine toxicity thresholds and cardiovascular wellness habits for active adults adds context for readers tracking this issue.
The standard safe daily caffeine limit for healthy adults is 400 mg. Further clinical trials are expected. Watch for updates as the AHA abstract advances through peer review.
(function () {
var btn = document.getElementById('karmactivePushBtn');
var status = document.getElementById('karmactivePushStatus');
if (!btn) return;
function setStatus(msg) {
if (status) status.textContent = msg;
}
function fallback() {
setStatus('Push notifications are not supported in this browser. Try the email option above.');
}
btn.addEventListener('click', function () {
try {
/\* OneSignal v16+ deferred SDK \*/
if (window.OneSignalDeferred && Array.isArray(window.OneSignalDeferred)) {
setStatus('Opening notification prompt...');
window.OneSignalDeferred.push(function (OneSignal) {
if (OneSignal && OneSignal.Notifications && typeof OneSignal.Notifications.requestPermission === 'function') {
OneSignal.Notifications.requestPermission()
.then(function () {
setStatus('You will receive push notifications when new articles are published.');
})
.catch(fallback);
} else {
fallback();
}
});
return;
}
/\* OneSignal direct object \*/
if (window.OneSignal && OneSignal.Notifications && typeof OneSignal.Notifications.requestPermission === 'function') {
OneSignal.Notifications.requestPermission()
.then(function () {
setStatus('You will receive push notifications when new articles are published.');
})
.catch(fallback);
return;
}
/\* Older OneSignal SDK \*/
if (window.OneSignal && typeof OneSignal.push === 'function') {
setStatus('Opening notification prompt...');
OneSignal.push(function () {
if (typeof OneSignal.showSlidedownPrompt === 'function') {
OneSignal.showSlidedownPrompt();
} else {
fallback();
}
});
return;
}
fallback();
} catch (e) {
fallback();
}
});
})();